Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

SAN FRANCISCO, Jan. 14, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory...

from PR Newswire: https://ift.tt/35TD4ID